Eli Lilly & Co. won another round in its legal battle with several generic pharmaceutical companies Tuesday when the Federal Circuit upheld a 2005 lower federal court ruling that found the company's patent on its anti-psychotic drug Zyprexa is valid. The generic drugmakers argued that the patent no longer was valid because discovery of the drug's molecular structure was obvious and that a previous Lilly patent had covered it, but the court said it found "no reversible error" and affirmed the ruling.
December 28, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Eli Lilly & Co. won another round in its legal battle with several generic pharmaceutical companies Tuesday when a federal appeals court upheld a 2005 lower federal court ruling that found the company’s patent on its anti-psychotic drug Zyprexa is valid.
The U.S. Court of Appeals for the Federal Circuit said it found “no reversible error” in an April 2005 ruling by a federal district court in Indiana and affirmed the ruling.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
